Kymera Therapeutics, Inc. (KYMR) › Cash & EquivalentsKymera Therapeutics, Inc. (KYMR) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $76.02M2020: $31.00M2021: $47.98M2022: $68.39M2023: $109.97M2024: $120.26M2025: $357.01M$357.01M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$357.01M+196.9%2024$120.26M+9.4%2023$109.97M+60.8%2022$68.39M+42.6%2021$47.98M+54.7%2020$31.00M-59.2%2019$76.02M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share